原发性肝癌患者血清p16和DAPK基因启动子甲基化的研究

 目的研究原发性肝癌患者血清p16和DAPK基因启动子甲基化的改变状况及其临床意义。方法运用甲基化特异性PCR技术,检测64例PLC患者血清p16基因和DAPK基因启动子甲基化,并分析与临床病理资料的关系。结果PLC患者血清p16基因和DAPK基因甲基化检出率分别为76.6%(49/64)和40.6%(26/64),而正常对照组和良性肝部疾病组血清未检出p16基因和DAPK基因甲基化;p16基因和DAPK基因甲基化检出率与HBsAg、分期及转移状态无明显关系,而与AFP有关联。结论p16基因和DAPK基因启动子异常甲基化参与了PLC的发生发展过程,并可作为PLC早期辅助诊断的分子标志物之一。

Analysis of Promoter Hypermethylation of p16 Gene and DAPK Gene in Sera from Primary Liver Cancer Patients

Objective To analyze the aberrant methylation of p16 gene and DAPK gene in sera from primary liver cancer patients and to evaluate the clinical significance. Methods A methylation-specific PCR was performed for the detection of promoter hypermethylation of p16 gene and DAPK gene in blood DNA from 64 cases of PLC patients. The relation of the aberrant methylation of p16 gene and DAPK gene and the clinical pathological data was analyzed. Results 76.6%(49/64)of the sera from 64 cases of PLC patients showed hypermethylation for p16 promoter and 40.6%(26/64)the same for DAPK promoter, whereas no methylated p16 gene and DAPK gene were found in sera from liver benign diseases patients and normal control. Methylated p16 gene and DAPK gene promoters in sera did not strongly correlate with HBsAg, stage ,metastasis and differentiation in PLC;but strongly correlated with AFP. Conclusion Detection of the aberrant methylation of p16 and DAPK gene in serum from PLC patients might offer an effective method for the earlier auxiliary diagnosis of the malignancy.